$MGRM
Monogram Technologies Inc

2024 Q2 Form 10-Q Financial Statement

#000141057824000765 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $1.208M $1.203M
YoY Change -59.74% -44.69%
% of Gross Profit
Research & Development $2.426M $2.407M
YoY Change -11.4% 39.89%
% of Gross Profit
Depreciation & Amortization $106.8K $105.9K
YoY Change 6.84% 3.31%
% of Gross Profit
Operating Expenses $3.634M $3.610M
YoY Change -36.68% -7.34%
Operating Profit -$3.634M -$3.610M
YoY Change -36.68% -7.34%
Interest Expense $96.07K $103.5K
YoY Change 60.12% 177.08%
% of Operating Profit
Other Income/Expense, Net $96.07K $103.5K
YoY Change -80.85% 177.04%
Pretax Income -$3.537M -$3.507M
YoY Change -32.45% -9.12%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.537M -$3.507M
YoY Change -32.45% -9.12%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11 -$0.11
Diluted Earnings Per Share -$0.11 -$0.11
COMMON SHARES
Basic Shares Outstanding 31.67M 31.63M
Diluted Shares Outstanding 31.56M 31.54M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.306M $10.08M
YoY Change -57.27% 30.56%
Cash & Equivalents $7.306M $10.08M
Short-Term Investments
Other Short-Term Assets $11.05K $466.4K
YoY Change -99.22% -16.04%
Inventory $297.7K
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $8.121M $10.71M
YoY Change -56.12% 29.41%
LONG-TERM ASSETS
Property, Plant & Equipment $848.7K $903.0K
YoY Change -16.85% -13.77%
Goodwill
YoY Change
Intangibles $443.8K $496.3K
YoY Change -32.12% -29.73%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.695M $1.834M
YoY Change -23.09% -20.75%
TOTAL ASSETS
Total Short-Term Assets $8.121M $10.71M
Total Long-Term Assets $1.695M $1.834M
Total Assets $9.817M $12.54M
YoY Change -52.6% 18.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.668M $1.321M
YoY Change 14.62% 11.98%
Accrued Expenses $677.4K $531.2K
YoY Change 90.9% 5.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.479M $1.984M
YoY Change -69.33% -78.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $296.0K $330.6K
YoY Change -31.17% -28.39%
Total Long-Term Liabilities $296.0K $330.6K
YoY Change -31.17% -28.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.479M $1.984M
Total Long-Term Liabilities $296.0K $330.6K
Total Liabilities $2.775M $2.314M
YoY Change -67.4% -76.34%
SHAREHOLDERS EQUITY
Retained Earnings -$58.55M -$55.02M
YoY Change 24.96% 32.18%
Common Stock $31.67K $31.63K
YoY Change 8.26% 227.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.042M $10.23M
YoY Change
Total Liabilities & Shareholders Equity $9.817M $12.54M
YoY Change -52.6% 18.44%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$3.537M -$3.507M
YoY Change -32.45% -9.12%
Depreciation, Depletion And Amortization $106.8K $105.9K
YoY Change 6.84% 3.31%
Cash From Operating Activities -$2.827M -$3.651M
YoY Change -52.0% 26.66%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $11.39K
YoY Change -100.0% -22.99%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$11.39K
YoY Change -100.0% -23.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 55.64K 150.7K
YoY Change -99.64% 2.49%
NET CHANGE
Cash From Operating Activities -2.827M -3.651M
Cash From Investing Activities 0.000 -11.39K
Cash From Financing Activities 55.64K 150.7K
Net Change In Cash -2.771M -3.511M
YoY Change -129.61% 27.68%
FREE CASH FLOW
Cash From Operating Activities -$2.827M -$3.651M
Capital Expenditures $0.00 $11.39K
Free Cash Flow -$2.827M -$3.662M
YoY Change -52.24% 26.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001769759
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31633995
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31338391
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41707
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Monogram Orthopaedics Inc.
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3913 Todd Lane
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78744
CY2024Q1 dei City Area Code
CityAreaCode
512
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
399-2656
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
MGRM
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31670375
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10077573
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13589028
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
364999
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
629751
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
664262
CY2024Q1 us-gaap Assets Current
AssetsCurrent
10707324
CY2023Q4 us-gaap Assets Current
AssetsCurrent
14618289
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
903011
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
945020
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
496250
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
548750
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
435116
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
466949
CY2024Q1 us-gaap Assets
Assets
12541701
CY2023Q4 us-gaap Assets
Assets
16579008
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1321313
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2462268
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
531239
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
227684
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
131081
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
128266
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1983633
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2818218
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
330561
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
363724
CY2024Q1 us-gaap Liabilities
Liabilities
2314194
CY2023Q4 us-gaap Liabilities
Liabilities
3181942
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31633995
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31338391
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
31634
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
31338
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65211241
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64874392
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55015368
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51508664
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10227507
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
13397066
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12541701
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16579008
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2406754
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1939551
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
119694
CY2023Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1132625
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1083711
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
822889
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
3610159
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
3895065
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3610159
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3895065
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2523
CY2024Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
103455
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
34820
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
103455
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
37343
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3506704
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3857722
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3506704
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3857722
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31535795
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31535795
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9673870
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9673870
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
13397066
CY2024Q1 mgrm Adjustments To Additional Paid In Capital Vesting Of Common Stock From Services Performed
AdjustmentsToAdditionalPaidInCapitalVestingOfCommonStockFromServicesPerformed
37500
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4746
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
294899
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3506704
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10227507
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4149176
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
147042
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
368140
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3857722
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
804636
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3506704
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-3857722
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
294899
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
368140
CY2024Q1 mgrm Other Expenses Settled With Stock Issuances
OtherExpensesSettledWithStockIssuances
37500
CY2024Q1 mgrm Fair Value Adjustment Of Common Stock Make Whole Obligation
FairValueAdjustmentOfCommonStockMakeWholeObligation
45252
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
105898
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
102503
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2523
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-364999
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
111445
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-231518
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1140955
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
516762
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
258303
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-243501
CY2024Q1 mgrm Increase Decrease In Operating Lease Assets And Liability Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilityNet
1485
CY2023Q1 mgrm Increase Decrease In Operating Lease Assets And Liability Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilityNet
2446
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3650768
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2882377
CY2024Q1 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
11389
CY2023Q1 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
14792
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11389
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14792
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
150702
CY2023Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
147042
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
150702
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
147042
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3511455
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2750127
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13589028
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10468645
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10077573
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7718518
CY2024Q1 mgrm Amortization Of Deferred Issuance Costs Of Common Stock Purchase Agreement
AmortizationOfDeferredIssuanceCostsOfCommonStockPurchaseAgreement
145956
CY2024Q1 mgrm Cashless Exercise Of Warrant
CashlessExerciseOfWarrant
246
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3506704
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55015368
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s most significant estimates relate to the fair value of the warrant liability, valuations of stock-based compensation, and the income tax valuation allowance. On a continual basis, management reviews its estimates, utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.</p>
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4885389
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24332213
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
145956
CY2024Q1 us-gaap Supplies
Supplies
163380
CY2023Q4 us-gaap Supplies
Supplies
163380
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
466371
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
354926
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
629751
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
664262
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 mgrm Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
246458
CY2024Q1 mgrm Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
246458
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.83
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.83
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
5200000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4904266
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.93
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20500
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.84
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
39377
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.65
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4885389
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.93
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2901918
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.75
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5466998
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001410578-24-000765-index-headers.html Edgar Link pending
0001410578-24-000765-index.html Edgar Link pending
0001410578-24-000765.txt Edgar Link pending
0001410578-24-000765-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mgrm-20240331.xsd Edgar Link pending
mgrm-20240331x10q.htm Edgar Link pending
mgrm-20240331xex10d23.htm Edgar Link pending
mgrm-20240331xex31d1.htm Edgar Link pending
mgrm-20240331xex31d2.htm Edgar Link pending
mgrm-20240331xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
mgrm-20240331_cal.xml Edgar Link unprocessable
mgrm-20240331x10q_htm.xml Edgar Link completed
mgrm-20240331_def.xml Edgar Link unprocessable
mgrm-20240331_lab.xml Edgar Link unprocessable
mgrm-20240331_pre.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending